{
    "nct_id": "NCT03546972",
    "official_title": "Choosing Health and Cancer Risk Reduction Through Good Eating and Exercise",
    "inclusion_criteria": "* Body Mass Index (BMI) >= 27 kg/m^2.\n* At high risk of developing breast cancer defined by one or more of the following: Gail model lifetime risk > 20% or a 5 year risk >1.66%, a history of deleterious BRCA1/2 mutation or mantle radiation, a history of ductal cancer in situ, or a history of high risk premalignant breast lesion.\n* 12 months without a period/menstrual cycle or having had a bilateral oophorectomy.\n* Ability to take digital time stamped photos.\n* Internet access (daily).\n* Reports being proficient in English (can read/write and speak fluently).\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 30 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Previous participation in this trial. Participation is defined as screening. Re-screening is not allowed except for individuals excluded for BMI. Patients previous screened as ineligible due to BMI are allowed to be re-screened and enrolled if eligible.\n* Has a current measured BMI less than 27 kg/m^2.\n* Reports being unwilling to use Continuous Glucose Monitor (CGM), which requires daily blood sampling by finger pricks.\n* Currently being actively treated for cancer other than nonmelanoma skin cancer.\n* Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests.\n* Reported current diagnosis or history of type I diabetes or type 2 diabetes.\n* Reported use of oral antidiabetic agents (OADs).\n* Current use of any drug (except metformin) or anticipated change in concomitant medication, which the investigator's opinion could interfere with the glucose metabolism (e.g. systemic corticosteroids).\n* Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator).\n* Previous or current treatment with GLP-1 receptor agonists (e.g. exenatide, liraglutide).\n* Fasting blood glucose level > 126 and glycosylated hemoglobin (HbA1c) > 7%.\n* Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.",
    "miscellaneous_criteria": ""
}